Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study

Table 5 Adjusted ^a log-transformed single-marker logistic regression model results

	Cases/n	β x IQR	OR^b	(95% CI)	p-value
CHF
Triglycerides	352/12,561	0.2614	1.299	1.057, 1.596	0.0128
CRP	859/28,214	0.6057	1.833	1.538, 2.183	<0.0001
Glycohemoglobin	869/28,390	0.1606	1.174	1.120, 1.232	<0.0001
Angina
Triglycerides	378/12,550	0.2520	1.287	1.067, 1.551	0.0083
CRP	888/28,211	0.2427	1.275	1.077, 1.509	0.0048
Glycohemoglobin	889/28,387	0.1430	1.154	1.099, 1.211	<0.0001
MI
Triglycerides	550/12,587	0.1389	1.149	0.982, 1.345	0.0833
CRP	1,239/28,261	0.2151	1.240	1.086, 1.417	0.0015
Glycohemoglobin	1,256/28,436	0.1446	1.156	1.112, 1.201	<0.0001
Stroke
Triglycerides	420/12,590	0.1297	1.139	0.952, 1.362	0.1565
CRP	966/28,270	0.3765	1.457	1.238, 1.715	<0.0001
Glycohemoglobin	985/28,447	0.1250	1.133	1.085, 1.184	<0.0001
CHD
Triglycerides	508/12,548	0.1681	1.183	1.021, 1.371	0.0251
CRP	1,186/28,175	0.1953	1.216	1.037, 1.425	0.0161
Glycohemoglobin	1,198/28,348	0.1708	1.186	1.142, 1.232	<0.0001

^aModels adjusted for age, sex, race/ethnicity, BMI, smoking status, systolic blood pressure, and family income.
^bOR estimates calculated for an IQR change in the respective biomarker, or an IQR in each biomarker for the joint effect estimates. IQRs for ln(Triglycerides, mg/dL) = 0.798 [corresponding to a 2.22 fold increase in non-transformed Triglycerides], ln(CRP, mg/dL) = 2.22 [corresponding to a 9.21 fold increase in non-transformed CRP], ln(Glycohemoglobin, %) = 0.0935 [corresponding to a 1.10 fold increase in non-transformed glycohemoglobin].

ISSN: 1478-7954